Telix Pharmaceuticals
Biotech · Healthcare
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Glioblastoma Trial
April 15, 2026
Telix Pharmaceuticals dosed the first patient with TLX101-Tx in the pivotal Phase 3 IPAX-BrIGHT trial for recurrent glioblastoma at Austin Health in Melbourne. This marks the first radiopharmaceutical therapy to enter Phase 3 for this aggressive brain cancer.
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.